Deanna L. Kelly
*To whom correspondence should be addressed; tel: 410-402-6860
fax: 410-402-6038
e-mail:
Name/email consistency: high
- Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Kelly, D.L., Raley, H.G., Lo, S., Wright, K., Liu, F., McMahon, R.P., Moolchan, E.T., Feldman, S., Richardson, C.M., Wehring, H.J., Heishman, S.J. Schizophr. Bull (2012)
- Cigarette smoking and mortality risk in people with schizophrenia. Kelly, D.L., McMahon, R.P., Wehring, H.J., Liu, F., Mackowick, K.M., Boggs, D.L., Warren, K.R., Feldman, S., Shim, J.C., Love, R.C., Dixon, L. Schizophr. Bull (2011)
- The impact of substance abuse on osteoporosis screening and risk of osteoporosis in women with psychotic disorders. Kelly, D.L., Myers, C.S., Abrams, M.T., Feldman, S., Park, J., McMahon, R.P., Shim, J.C. Osteoporos. Int (2011)
- Effects of the cannabinoid-1 receptor antagonist rimonabant on psychiatric symptoms in overweight people with schizophrenia: a randomized, double-blind, pilot study. Kelly, D.L., Gorelick, D.A., Conley, R.R., Boggs, D.L., Linthicum, J., Liu, F., Feldman, S., Ball, M.P., Wehring, H.J., McMahon, R.P., Huestis, M.A., Heishman, S.J., Warren, K.R., Buchanan, R.W. J. Clin. Psychopharmacol (2011)
- Nonresponse to clozapine and premorbid functioning in treatment of refractory schizophrenia. Kelly, D.L., Feldman, S., Boggs, D.L., Gale, E., Conley, R.R. Compr. Psychiatry (2010)
- Cardiovascular disease mortality in patients with chronic schizophrenia treated with clozapine: a retrospective cohort study. Kelly, D.L., McMahon, R.P., Liu, F., Love, R.C., Wehring, H.J., Shim, J.C., Warren, K.R., Conley, R.R. J. Clin. Psychiatry (2010)
- Remission in schizophrenia: the relationship to baseline symptoms and changes in symptom domains during a one-year study. Kelly, D.L., Weiner, E., Ball, M.P., McMahon, R.P., Carpenter, W.T., Buchanan, R.W. J. Psychopharmacol. (Oxford) (2009)
- A randomized double-blind trial of atomoxetine for cognitive impairments in 32 people with schizophrenia. Kelly, D.L., Buchanan, R.W., Boggs, D.L., McMahon, R.P., Dickinson, D., Nelson, M., Gold, J.M., Ball, M.P., Feldman, S., Liu, F., Conley, R.R. J. Clin. Psychiatry (2009)
- Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone. Kelly, D.L., Wehring, H.J., Linthicum, J., Feldman, S., McMahon, R.P., Love, R.C., Wagner, T., Shim, J.C., Fowler, D.R. Schizophr. Res. (2009)
- Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia. Kelly, D.L., McMahon, R.P., Weiner, E., Boggs, D.L., Dickinson, D., Conley, R.R., Buchanan, R.W. Schizophr. Res. (2008)
- Metabolic risk with second-generation antipsychotic treatment: a double-blind randomized 8-week trial of risperidone and olanzapine. Kelly, D.L., Conley, R.R., Love, R.C., Morrison, J.A., McMahon, R.P. Ann. Clin. Psychiatry (2008)
- Clozapine underutilization and discontinuation in African Americans due to leucopenia. Kelly, D.L., Kreyenbuhl, J., Dixon, L., Love, R.C., Medoff, D., Conley, R.R. Schizophr. Bull (2007)
- Reaching for wellness in schizophrenia. Kelly, D.L., Boggs, D.L., Conley, R.R. Psychiatr. Clin. North Am. (2007)
- Clozapine utilization and outcomes by race in a public mental health system: 1994-2000. Kelly, D.L., Dixon, L.B., Kreyenbuhl, J.A., Medoff, D., Lehman, A.F., Love, R.C., Brown, C.H., Conley, R.R. J. Clin. Psychiatry (2006)
- A randomized double-blind 12-week study of quetiapine, risperidone or fluphenazine on sexual functioning in people with schizophrenia. Kelly, D.L., Conley, R.R. Psychoneuroendocrinology (2006)
- Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Kelly, D.L., Conley, R.R., Feldman, S., Yu, Y., McMahon, R.P., Richardson, C.M. Psychiatr. Q (2006)
- Treatment considerations in women with schizophrenia. Kelly, D.L. J. Womens. Health. (Larchmt) (2006)
- Thyroid function in treatment-resistant schizophrenia patients treated with quetiapine, risperidone, or fluphenazine. Kelly, D.L., Conley, R.R. J. Clin. Psychiatry (2005)
- First-episode schizophrenia: a focus on pharmacological treatment and safety considerations. Kelly, D.L., Conley, R.R., Carpenter, W.T. Drugs (2005)
- Atypical antipsychotic use in a state hospital inpatient adolescent population. Kelly, D.L., Love, R.C., MacKowick, M., McMahon, R.P., Conley, R.R. J. Child. Adolesc. Psychopharmacol (2004)
- Lifetime psychiatric symptoms in persons with schizophrenia who died by suicide compared to other means of death. Kelly, D.L., Shim, J.C., Feldman, S.M., Yu, Y., Conley, R.R. J. Psychiatr. Res (2004)
- Sexuality and schizophrenia: a review. Kelly, D.L., Conley, R.R. Schizophr. Bull (2004)
- Clozapine treatment in patients with prior substance abuse. Kelly, D.L., Gale, E.A., Conley, R.R. Can. J. Psychiatry (2003)
- Adverse effects and laboratory parameters of high-dose olanzapine vs. clozapine in treatment-resistant schizophrenia. Kelly, D.L., Conley, R.R., Richardson, C.M., Tamminga, C.A., Carpenter, W.T. Ann. Clin. Psychiatry (2003)
- Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Kelly, D.L., Nelson, M.W., Love, R.C., Yu, Y., Conley, R.R. Psychiatr. Serv (2001)
- Ziprasidone and the QTc interval: pharmacokinetic and pharmacodynamic considerations. Kelly, D.L., Love, R.C. Psychopharmacol. Bull (2001)
